Literature DB >> 32585160

Advances in functional and molecular MRI technologies in chronic liver diseases.

Iris Y Zhou1, Onofrio A Catalano2, Peter Caravan3.   

Abstract

MRI has emerged as the most comprehensive non-invasive diagnostic tool for liver diseases. In recent years, the value of MRI in hepatology has been significantly enhanced by a wide range of contrast agents, both clinically available and under development, that add functional information to anatomically detailed morphological images, or increase the distinction between normal and pathological tissues by targeting molecular and cellular events. Several classes of contrast agents are available for contrast-enhanced hepatic MRI, including i) conventional non-specific extracellular fluid contrast agents for assessing tissue perfusion; ii) hepatobiliary-specific contrast agents that are taken up by functioning hepatocytes and excreted through the biliary system for evaluating hepatobiliary function; iii) superparamagnetic iron oxide particles that accumulate in Kupffer cells; and iv) novel molecular contrast agents that are biochemically targeted to specific molecular/cellular processes for staging liver diseases or detecting treatment responses. The use of different functional and molecular MRI methods enables the non-invasive assessment of disease burden, progression, and treatment response in a variety of liver diseases. A high diagnostic performance can be achieved with MRI by combining imaging biomarkers.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic liver diseases; Contrast agents; Fibrosis; Functional imaging; Hepatocyte function; MRI; Molecular imaging; Perfusion imaging

Year:  2020        PMID: 32585160      PMCID: PMC7572718          DOI: 10.1016/j.jhep.2020.06.020

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  149 in total

Review 1.  Liver biopsy.

Authors:  A A Bravo; S G Sheth; S Chopra
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

Review 2.  Magnetic resonance imaging of liver tumors.

Authors:  Riccardo Lencioni; Dania Cioni; Laura Crocetti; Clotilde Della Pina; Carlo Bartolozzi
Journal:  J Hepatol       Date:  2004-01       Impact factor: 25.083

Review 3.  Magnetic resonance imaging measurement of iron overload.

Authors:  John C Wood
Journal:  Curr Opin Hematol       Date:  2007-05       Impact factor: 3.284

4.  Pre-treatment estimation of future remnant liver function using gadoxetic acid MRI in patients with HCC.

Authors:  Jeong Hee Yoon; Joon-Il Choi; Yong Yeon Jeong; Andrea Schenk; Longquan Chen; Hendrik Laue; So Yeon Kim; Jeong Min Lee
Journal:  J Hepatol       Date:  2016-07-28       Impact factor: 25.083

Review 5.  Coagulation and coagulation signalling in fibrosis.

Authors:  Paul F Mercer; Rachel C Chambers
Journal:  Biochim Biophys Acta       Date:  2013-01-05

6.  Vasculitis: molecular imaging by targeting the inflammatory enzyme myeloperoxidase.

Authors:  Henry S Su; Matthias Nahrendorf; Peter Panizzi; Michael O Breckwoldt; Elisenda Rodriguez; Yoshiko Iwamoto; Elena Aikawa; Ralph Weissleder; John W Chen
Journal:  Radiology       Date:  2011-11-14       Impact factor: 11.105

7.  3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model.

Authors:  Christian T Farrar; Danielle K DePeralta; Helen Day; Tyson A Rietz; Lan Wei; Gregory Y Lauwers; Boris Keil; Arun Subramaniam; Anthony J Sinskey; Kenneth K Tanabe; Bryan C Fuchs; Peter Caravan
Journal:  J Hepatol       Date:  2015-05-25       Impact factor: 25.083

8.  Activatable magnetic resonance imaging agents for myeloperoxidase sensing: mechanism of activation, stability, and toxicity.

Authors:  Elisenda Rodríguez; Mark Nilges; Ralph Weissleder; John W Chen
Journal:  J Am Chem Soc       Date:  2010-01-13       Impact factor: 15.419

9.  Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis.

Authors:  Sander S Rensen; Yanti Slaats; Jeroen Nijhuis; Anneke Jans; Veerle Bieghs; Ann Driessen; Ernst Malle; Jan Willem Greve; Wim A Buurman
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

10.  Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist.

Authors:  Derek J Erstad; Christian T Farrar; Sarani Ghoshal; Ricard Masia; Diego S Ferreira; Yin-Ching Iris Chen; Ji-Kyung Choi; Lan Wei; Phillip A Waghorn; Nicholas J Rotile; Chuantao Tu; Katherine A Graham-O'Regan; Mozhdeh Sojoodi; Shen Li; Yang Li; Guogiang Wang; Kathleen E Corey; Yat Sun Or; Lijuan Jiang; Kenneth K Tanabe; Peter Caravan; Bryan C Fuchs
Journal:  Hepatol Commun       Date:  2018-05-21
View more
  3 in total

1.  Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis.

Authors:  Philip A Waghorn; Diego S Ferreira; Derek J Erstad; Nicholas J Rotile; Ricard Masia; Chloe M Jones; Chuantao Tu; Mozhdeh Sojoodi; Yin-Ching I Chen; Franklin Schlerman; Jeremy Wellen; Robert V P Martinez; Kenneth K Tanabe; Bryan C Fuchs; Peter Caravan
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

2.  Concentrations and pharmacokinetic parameters of MRI and SPECT hepatobiliary agents in rat liver compartments.

Authors:  Catherine M Pastor; Florian Joly; Valérie Vilgrain; Philippe Millet
Journal:  Eur Radiol Exp       Date:  2021-09-21

Review 3.  Assessment of Liver Function With MRI: Where Do We Stand?

Authors:  Carolina Río Bártulos; Karin Senk; Mona Schumacher; Jan Plath; Nico Kaiser; Ragnar Bade; Jan Woetzel; Philipp Wiggermann
Journal:  Front Med (Lausanne)       Date:  2022-04-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.